BlinkLab (ASX:BB1), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism, announced that it had initiated a clinical study in partnership with US-based Turning Pointe Autism Foundation.
The study will enrol up to one hundred children previously diagnosed with autism and one hundred children without an autism diagnosis. The data obtained during the course of this collaboration will be used to finalize the data collection and processing algorithms as well as artificial intelligence/machine learning (AI/ML) models ahead of the FDA registrational study expected to start in the second half of 2024.
- Strategic partnership initiated with US-based Turning Pointe Autism Foundation, to conduct a clinical study using AI-powered diagnostic tools developed for autism.
- The study will involve up to two hundred children aiming to finalize the AI/ML algorithms and models for a larger FDA registration study planned for the second half of 2024.
- This study aligns with regulatory preparations, setting the stage for an FDA registrational study.
- The collaboration agreement ensures that any intellectual property developed as a direct result of the partnership will be owned by BlinkLab.
Henk-Jan Boele, CEO of BlinkLab commented: “Our partnership with Turning Pointe is more than just collaboration. It is a major step toward fulfilling our mission to make well-established neurobehavioral testing clinically accessible and efficient. Turning Pointe’s dedication to quality education and support aligns perfectly with our goal of leveraging cutting-edge technology to better understand and assist individuals with autism. We are very excited about the possibilities that this collaboration offers for the advancement of autism diagnosis and care.”